Net revenue growth remained weak during the quarter, impacted by cautious investment decisions in capital equipment within certain product categories and by geopolitical uncertainty. In the second quarter, net revenue decreased by 5.0 percent in constant currency. At the same time, order intake increased by 1.8 percent in constant currency, which gives us confidence for … Read more
Weak sales, strongly negatively impacted by currency effects and global uncertainty. In the first quarter, sales decreased by 7.2 per cent in constant currency. Order intake developed well with growth of 13.3 per cent in local currency, which gives us a stronger starting point for the coming periods. Cash flow from operating activities improved by … Read more
Increased profits, profitability and stable cash flow. In the fourth quarter, organic sales increased by 4.0% in constant currency and an increase of 1.5% for the full year 2025. Our focus on operational efficiency during the year means that EBITA increased by SEK 5.1 million in the fourth quarter, while the EBITA margin amounted to … Read more
Strengthened profitability and cash flow despite a quarter with macro headwinds. In the third quarter, organic sales decreased by 4.8% in constant currency, but the year-to-date growth remains positive. The work on operational efficiency is having an effect and EBITA increased by SEK 1.0 million while the EBITA margin amounted to 15.5% (13.7%). Cash flow … Read more
In the second quarter of 2025, organic sales adjusted for currency effects increased, driven by steady demand for laboratory equipment and rental of equipment for clinical studies. Operating cash flow improved in the quarter, and EBITA was in line with last year with a stronger margin. Through the new capital structure, ADDvise’s annual interest expenses … Read more
In the first quarter of 2025, net revenue increased organically with continued good profitability, which shows stable demand in medical technology and laboratory solutions. Cash flow from operating activities was strong, driven by improved working capital while EBITA, the company’s new main profit measure, decreased compared to the same quarter last year. Through increased operational … Read more
The fourth quarter of 2024 showed a turnaround in organic net revenue. In December alone, we are now back at positive organic growth of 4.8%. With new long-term financial targets, we are now taking the next step in the company’s development, with a continued focus on profitable growth, stable returns and well-balanced debt. October–December 2024 … Read more
The third quarter of 2024 showed strong order intake, +17%, and net revenue growth, +26%. Despite challenging comparative figures from 2023, especially in the pharmaceutical sector and rental of equipment for clinical trials, we showed robust development. Excluding these segments, we saw organic growth of 6% for January−September, reflecting the strength of our business. July–September … Read more
The second quarter saw continued robust revenue growth and improved profit. Organic growth remains burdened by challenging comparables from 2023 driven by very strong sales in pharmaceuticals and rental of equipment for clinical trials, but with organic order intake well back in positive territory with several large new orders, we are optimistic about the second … Read more
The first quarter saw a continued favourable revenue development. The Lab segment delivered strong organic growth whereas our pharmaceuticals business affected the Group negatively. The changing product mix resulted in lower margins. Work continued to optimise the capital structure and profit for the period improved. January – March 2024 Net revenue for the period was … Read more